Opportunity Information: Apply for RFA HG 10 012
Apply for RFA HG 10 012
- The National Institutes of Health in the health sector is offering a public funding opportunity titled "Revolutionary Genome Sequencing Technologies The 1000 Genome (R01)" and is now available to receive applicants.
- Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.172 Human Genome Research.
- This funding opportunity was created on Aug 27, 2010 and posted on Aug 27, 2010.
- Applicants must submit their applications by Oct 17, 2012. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
- Eligible applicants include: Private institutions of higher education Small businesses Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education Public and State controlled institutions of higher education Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education State governments Others (see text field entitled Additional Information on Eligibility for clarification).
- Other Eligible Applicants include the following Eligible Agencies of the Federal Government Non domestic (non U.S.) Entities (Foreign Organizations).
[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal:
Opportunity Summary:
This funding opportunity, titled "Revolutionary Genome Sequencing Technologies: The 1000 Genome (R01)" (Funding Opportunity Number RFA-HG-10-012), is an NIH/National Human Genome Research Institute (NHGRI) solicitation for R01 research project grant applications focused on radically advancing DNA sequencing technology. The central purpose is to drive the development of new approaches that can deliver extremely low-cost, high-quality genome sequencing, with a specific headline target: bringing the cost of sequencing a mammalian-sized genome down to roughly $1,000. In practical terms, NHGRI is looking for technology that meaningfully changes the cost and performance curve for whole-genome sequencing, not incremental improvements that leave major cost or quality barriers in place.
Applicants are encouraged to propose either complete, end-to-end sequencing platforms or research aimed at solving major bottlenecks in critical components of a sequencing system. That means proposals can range from fully integrated hardware, chemistry, and computational pipelines, to focused projects that tackle specific high-impact hurdles (for example, improving accuracy, throughput, sample preparation, signal detection, read length, error correction, or other enabling steps that determine whether a system can realistically hit the $1,000 genome goal). The announcement explicitly welcomes exploration of methods beyond the mainstream approaches being pursued at the time, signaling that unconventional ideas and alternative technical routes are not only allowed but encouraged if they plausibly support a step-change in cost and quality.
A notable feature of this FOA is its emphasis on high risk/high payoff research. NHGRI indicates that ambitious, potentially transformative projects are appropriate, with the programmatic goal of achieving the initiative's objectives by approximately 2014. In other words, this is meant to accelerate breakthroughs rather than fund only safe, incremental technology development. The opportunity is categorized under health research (CFDA 93.172, Human Genome Research) and uses the NIH R01 mechanism, which is generally intended for more substantial, hypothesis-driven or technology-development projects with a defined plan and clear milestones.
This R01 funding opportunity runs in parallel with other solicitations that share the same scientific scope but use different award mechanisms: RFA-HG-10-013 (R21) and RFA-HG-10-014 (R43/R44). That structure provides multiple entry points depending on project maturity and applicant type, with R01 positioned for more developed and comprehensive efforts, R21 for exploratory/developmental work, and R43/R44 for small business innovation projects.
On funding levels, NHGRI anticipated making approximately 2 to 7 awards under this FOA, contingent on available funds and the quality and number of applications received. The institute projected up to $5 million in total costs to be awarded in each of FY2011, FY2012, and FY2013 in response to this announcement, again depending on appropriations and merit. There is no cost sharing or matching requirement, which is typical for many NIH research grants and reduces financial barriers for applicants.
Eligibility is broad and includes private and public institutions of higher education, state and local government entities as described, small businesses, and nonprofit organizations (including both 501(c)(3) and certain non-501(c)(3) nonprofits). The eligibility language also extends to other entities described in the full announcement, including eligible federal agencies and non-U.S. organizations (foreign organizations), which indicates that NHGRI was open to funding strong proposals regardless of whether the applicant organization was domestic, so long as NIH rules and the FOA's specific requirements were met.
Administratively, the opportunity was posted on August 27, 2010, with an original and current closing date of October 17, 2012, and an archive date of November 17, 2012. The full announcement was hosted through the NIH Grants Guide, and the notice provides contact pathways through the NIH Office of Extramural Research (OER) for technical issues accessing or linking to the announcement. Overall, the FOA is best understood as a targeted push by NHGRI to catalyze next-generation sequencing breakthroughs capable of making whole-genome sequencing dramatically cheaper while maintaining or improving data quality, with an explicit invitation for bold technical ideas that could plausibly enable the $1,000 mammalian genome.
Frequently Asked Questions (FAQs)
What is the name of this funding opportunity?
The funding opportunity is titled "Revolutionary Genome Sequencing Technologies: The 1000 Genome (R01)."
What is the funding opportunity number (FOA number)?
The Funding Opportunity Number is RFA-HG-10-012.
Which agency and institute are offering this opportunity?
This is a National Institutes of Health (NIH) solicitation offered through the National Human Genome Research Institute (NHGRI).
What grant mechanism does this opportunity use?
This opportunity uses the NIH R01 research project grant mechanism.
What is the main goal of the FOA?
The central goal is to radically advance DNA sequencing technology to enable extremely low-cost, high-quality whole-genome sequencing, with a headline target of reducing the cost of sequencing a mammalian-sized genome to roughly $1,000.
Is the FOA looking for incremental improvements to existing sequencing methods?
No. The FOA emphasizes meaningful changes to the cost and performance curve for whole-genome sequencing rather than incremental improvements that leave major cost or quality barriers in place.
What kinds of projects are encouraged under this FOA?
Applicants are encouraged to propose either complete, end-to-end sequencing platforms or research focused on solving major bottlenecks in critical components of a sequencing system.
Can an application focus on only one part of a sequencing system rather than an entire platform?
Yes. The FOA allows projects that target major, high-impact hurdles in key components or steps that determine whether a system can realistically meet the $1,000 genome goal.
What are examples of bottlenecks or components that a project could address?
Examples mentioned include improving accuracy, throughput, sample preparation, signal detection, read length, error correction, and other enabling steps that affect cost and data quality.
Are unconventional or non-mainstream sequencing approaches allowed?
Yes. The announcement explicitly welcomes exploration of methods beyond mainstream approaches and encourages unconventional ideas if they plausibly support a step-change in cost and quality.
Does NHGRI emphasize high-risk, high-payoff research in this FOA?
Yes. A notable feature is the emphasis on high risk/high payoff research, with ambitious and potentially transformative projects considered appropriate.
What is the targeted timeframe for achieving the initiative objectives?
The FOA describes a programmatic goal of achieving the initiative's objectives by approximately 2014.
What program area or category is associated with this opportunity?
The opportunity is categorized under health research and is associated with CFDA 93.172 (Human Genome Research).
How many awards did NHGRI anticipate making under this FOA?
NHGRI anticipated making approximately 2 to 7 awards, depending on available funds and the quality and number of applications received.
What funding level did NHGRI project for this FOA?
NHGRI projected up to $5 million in total costs to be awarded in each of FY2011, FY2012, and FY2013 in response to this announcement, contingent on appropriations and application merit.
Is cost sharing or matching required?
No. The FOA states there is no cost sharing or matching requirement.
Who is eligible to apply?
Eligibility is broad and includes private and public institutions of higher education, state and local government entities (as described), small businesses, and nonprofit organizations (including both 501(c)(3) and certain non-501(c)(3) nonprofits). The eligibility language also extends to other entities described in the full announcement, including eligible federal agencies and non-U.S. organizations (foreign organizations).
Are non-U.S. (foreign) organizations eligible?
Yes. The provided summary indicates the eligibility language includes non-U.S. organizations (foreign organizations), subject to NIH rules and the FOA's specific requirements.
Are small businesses eligible under this R01 FOA?
Yes. Small businesses are included in the broad eligibility statement for this opportunity.
Are there related funding opportunities with the same scientific scope but different mechanisms?
Yes. This R01 FOA runs in parallel with other solicitations sharing the same scientific scope: RFA-HG-10-013 (R21) and RFA-HG-10-014 (R43/R44).
How does this R01 relate to the companion R21 and R43/R44 opportunities?
Based on the description provided: R01 is positioned for more developed and comprehensive efforts, R21 is for exploratory/developmental work, and R43/R44 is for small business innovation projects.
When was this funding opportunity posted?
The opportunity was posted on August 27, 2010.
What was the closing date for applications?
The original and current closing date was October 17, 2012.
When was the FOA archived?
The archive date was November 17, 2012.
Where was the full announcement hosted?
The full announcement was hosted through the NIH Grants Guide.
Where can applicants get help with technical issues accessing or linking to the announcement?
The notice provides contact pathways through the NIH Office of Extramural Research (OER) for technical issues related to accessing or linking to the announcement.
What is the overall intent of this FOA in plain terms?
Overall, the FOA is a targeted push by NHGRI to catalyze next-generation sequencing breakthroughs that can make whole-genome sequencing dramatically cheaper while maintaining or improving data quality, with an explicit invitation for bold technical ideas that could plausibly enable the $1,000 mammalian genome.
Browse more opportunities from the same category: Health
Next opportunity: Revolutionary Genome Sequencing Technologies The 1000 Genome (R21)
Previous opportunity: Global Undergraduate Exchange Program in Eurasia and Central Asia
USGrants.org Applicant Portal:
Are you interested in learning about about how to apply for this government funding opportunity? You can create a free applicant account and receive instant access to our applicant portal that many business owners like you have benefited from.
Apply for RFA HG 10 012
[Watch] how do funding administrators access proposals?
Applicants also applied for:
Applicants who have applied for this opportunity (RFA HG 10 012) also looked into and applied for these:
| Funding Opportunity |
|---|
| Revolutionary Genome Sequencing Technologies The 1000 Genome (R21) Apply for RFA HG 10 013 Funding Number: RFA HG 10 013 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Revolutionary Genome Sequencing Technologies The 1000 Genome (SBIR R43/R44) Apply for RFA HG 10 014 Funding Number: RFA HG 10 014 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| National Spina Bifida Patient Registry Clinic Demonstration Project (U01) Apply for RFA DD 11 001 Funding Number: RFA DD 11 001 Agency: Centers for Disease Control and Prevention Category: Health Funding Amount: $40,000 |
| Ancillary Studies to Large Ongoing Clinical Projects (R01) Apply for RFA AR 11 012 Funding Number: RFA AR 11 012 Agency: National Institutes of Health Category: Health Funding Amount: $250,000 |
| Ancillary Studies to Large Ongoing Clinical Projects (R21) Apply for RFA AR 11 013 Funding Number: RFA AR 11 013 Agency: National Institutes of Health Category: Health Funding Amount: $200,000 |
| Protein Structure InitiativeBiology Materials Repository (PSIBiology MR) (U01) Apply for RFA GM 11 008 Funding Number: RFA GM 11 008 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| NIOSH Support for Conferences and Scientific Meetings (R13) Apply for PAR 10 272 Funding Number: PAR 10 272 Agency: Centers for Disease Control and Prevention Category: Health Funding Amount: $20,000 |
| Mind/Body Research Program (R01) Apply for CDC RFA DP 10 010 Funding Number: CDC RFA DP 10 010 Agency: Centers for Disease Control and Prevention Category: Health Funding Amount: $45,000 |
| Mind/Body Research Program (R01) Apply for CDC RFA DP10 010 Funding Number: CDC RFA DP10 010 Agency: Centers for Disease Control and Prevention Category: Health Funding Amount: Case Dependent |
| Planning Grant for Chronic, Non Communicable Diseases and Disorders Across the Lifespan Fogarty International Research Training Planning Award (NCD LIFESPAN) (D71) Apply for PAR 10 277 Funding Number: PAR 10 277 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Dynamics of Host Associated Microbial Communities (R01) Apply for RFA GM 12 001 Funding Number: RFA GM 12 001 Agency: National Institutes of Health Category: Health Funding Amount: $250,000 |
| NIDCD Otopathology Research Collaboration Network (U24) Apply for RFA DC 11 003 Funding Number: RFA DC 11 003 Agency: National Institutes of Health Category: Health Funding Amount: $300,000 |
| NIAAA Collaborative Centers for HIV/AIDS and Alcohol Outcomes Research (U01, U24) Apply for RFA AA 11 003 Funding Number: RFA AA 11 003 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Healthy Tomorrows Partnership For Children Program Apply for HRSA 11 029 Funding Number: HRSA 11 029 Agency: Health Resources and Services Administration Category: Health Funding Amount: $50,000 |
| Program Projects for Collaborative Research on the Basic Biology of Pluripotency and Reprogramming (P01) Apply for RFA GM 11 005 Funding Number: RFA GM 11 005 Agency: National Institutes of Health Category: Health Funding Amount: $100,000 |
| Collaborative Hubs for International Research on Mental Health (U19) Apply for RFA MH 11 070 Funding Number: RFA MH 11 070 Agency: National Institutes of Health Category: Health Funding Amount: $500,000 |
| NEI Translational Research Program on Therapy for Visual Disorders (R24) Apply for PAR 10 281 Funding Number: PAR 10 281 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Pilot and Feasibility Clinical Research Grants in Arthritis and Musculoskeletal and Skin Diseases (R21) Apply for PAR 10 282 Funding Number: PAR 10 282 Agency: National Institutes of Health Category: Health Funding Amount: $200,000 |
| Ryan White Part B Supplemental Apply for HRSA 11 099 Funding Number: HRSA 11 099 Agency: Health Resources and Services Administration Category: Health Funding Amount: Case Dependent |
| National Institute on Aging Revision Requests for Active Program Projects (P01) Apply for PAR 10 284 Funding Number: PAR 10 284 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
Grant application guides and resources
It is always free to apply for government grants. However the process may be very complex depending on the funding opportunity you are applying for. Let us help you!
Apply for Grants
Premium leads for funding administrators, grant writers, and loan issuers
Thousands of people visit our website for their funding needs every day. When a user creates a grant proposal and files for submission, we pass the information on to funding administrators, grant writers, and government loan issuers.
If you manage government grant programs, provide grant writing services, or issue personal or government loans, we can help you reach your audience.
Subscribe to Leads
Request more information:
Would you like to learn more about this funding opportunity, similar opportunities to "RFA HG 10 012", eligibility, application service, and/or application tips? Submit an inquiry below:
Don't forget to subscribe to our grant alerts mailing list to receive weekly alerts on new and updated grant funding opportunities like this one in your email.